Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Brain Cancer and Brain Injury Drive Systemic Immunosuppression
    ABSTRACT & COMMENTARY

    Brain Cancer and Brain Injury Drive Systemic Immunosuppression

    April 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Status Epilepticus in Cancer Patients: Does It Make a Difference If the Tumor is a Primary Brain Tumor or Systemic Metastasis?

    Optimizing Brain Oxygen in Severe Traumatic Brain Injury

    Significance of Brain Microbleeds After Traumatic Brain Injury

    Related Products

    EEG Reactivity Testing in Comatose Patients After Severe Brain Injury

    Sleep Disorders Associated with Traumatic Brain Injury

    Mechanisms of Tissue Hypoxia and Cerebral Ischemia in Traumatic Brain Injury

    Keywords

    brain

    glioblastoma

    immunosuppression

    t-cell

    thymus

    By Evan Noch, MD, PhD

    Instructor, Department of Neurology, Weill Cornell Medical College

    SYNOPSIS: Glioblastoma-associated immunosuppression is a significant factor associated with poor survival in this disease. Accumulating evidence suggests that mouse models of glioblastoma and other brain cancers induce systemic immunosuppression through dysregulation of a newly recognized brain-thymus axis and that targeting this pathway may promote more effective immune surveillance of these tumors.

    SOURCE: Ayasoufi K, Pfaller CK, Evgin L, et al. Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain 2020;143:3629-3652.

    Systemic immunosuppression is a strong deter-minant of poor prognosis in a variety of human cancers. Glioblastoma patients exhibit decreased immune surveillance, mediated by dysregulation of T-cell repertoires and reduced expression of major histocompatibility complex class II (MHCII) expression, leading to unchecked tumor growth. Consequently, although immunotherapy to promote immune-mediated attack and clearance of tumor cells has benefited other cancer patients, immunotherapy has not shown any long-term benefit in glioblastoma. The biological pathways that mediate systemic immunosuppression in glioblastoma remain incompletely understood, and therapeutic targets to promote immune cell retention and function are unknown.

    Ayasoufi et al demonstrated a glioblastoma-thymus-adrenal gland axis that regulates systemic immunosuppression in response to brain tumor and brain injury models. They used a variety of brain tumor models, including the GL261 murine glioma model, a transgenic murine diffuse intrinsic pontine glioma model, and an intracranial B16 murine melanoma model. Tumors from each of these models significantly reduced thymus size and cellularity. Functionally, thymic T-cells from these mice were reduced and exhibited decreased late-stage proliferation, while B-cell numbers were increased in atrophic thymus. Next-generation sequencing of thymus from GL261-bearing mice demonstrated upregulation of T-cell proliferation programs but downregulation of deoxyribonucleic acid (DNA) replication and elongation, providing a likely cause of T-cell loss in these models. Interestingly, pathway analysis showed that ribonucleic acid (RNA) molecules associated with cancer development, particularly that of gliomas, were found among thymic bulk RNA transcripts.

    To investigate systemic immunosuppression associated with brain tumor development, the authors measured immune cell numbers and phenotypes in tumor-bearing mice. They found that CD4+ and CD8+ T-cells and MHCII-expressing B-cells and monocytes/macrophages were reduced in these mice, indicating deficits in both innate and adaptive immunity. Using the technique of parabiosis to study circulating factors mediating brain tumor-induced immunosuppression, the authors joined GFP-expressing C57BL/6 mice to wild-type C57BL/6 mice. Although they implanted GL261 cells into the brain of only one parabiont, both mice exhibited thymic involution, reduced peripheral blood CD4+ T-cell counts, and decreased MHCII expression levels. Reinforcing the findings of the parabiotic model, the authors found that serum derived from GL261-bearing mice, but not from GL261 cells grown in vitro, inhibited T-cell proliferation in culture systems.

    Expanding their observations from gliomagenesis to models of brain injury, the authors found that thymic involution occurs in response to experimental models of demyelination, lipopolysaccharide-induced neuroinflammation, kainic acid-induced seizures, and even mechanical injury mediated by intracranial phosphate-buffered saline injection. When mice recovered from these acute injuries, the thymus recovered also, resembling those of naïve control mice. Similar to the deleterious effects of sera from tumor-bearing mice on T-cell proliferation in vitro, the researchers found that sera from acutely injured but not recovered mice robustly inhibited T-cell proliferation. These findings indicate the presence of soluble factors that induce immunosuppression in response to brain injury.

    Since stress hormones produced by the adrenal glands may mediate the sequelae of brain injury, the investigators studied tumor-induced immunosuppression in adrenalectomized mice. Surprisingly, they found that adrenalectomized mice exhibited increased numbers, but not frequencies, of immune cells in the blood, thymus, and spleen. When they implanted GL261 cells into the brains of mice, they found no evidence of thymic involution, disruptions in T-cell development, or sequestration of T-cells in the bone marrow. However, this rescue of immune function in adrenalectomized mice did not affect overall survival.

    To determine the soluble factors that mediate immunosuppression, they filtered sera from glioma-bearing mice based on molecular weight and added this filtrate to cultured T-cells. Large factors with molecular weights greater than 100 kDa inhibited T-cell growth, but small molecules less than 3 kDa were not immunosuppressive. To confirm that cortisol, a small molecule stress hormone, does not induce adrenal-mediated reduction in thymic function, the researchers tested the effects of serum from wild-type and adrenalectomized mice on T-cell growth in vitro. Serum from both mouse cohorts was equally immunosuppressive, but serum from naïve adrenalectomized mice did not inhibit T-cell growth. These findings suggest that, although adrenalectomized tumor-bearing mice do not show thymic phenotypic changes, these mice exhibit thymus-independent immunosuppression from the action of a large molecular weight soluble factor associated with poor survival.

    COMMENTARY

    Immunosuppression in glioblastoma facilitates tumor escape from immune surveillance. By establishing a new brain-thymus-adrenal gland axis through which brain tumors and brain injury mediate thymic involution, decreased peripheral immune cell counts, and the circulation of immunosuppressive serum-derived soluble factors, the authors of this study have identified a putative target to improve immune function in these patients. Such targeted treatments also could improve the efficacy of systemic immunotherapy in this disease. The identity of the large molecular weight soluble factors mediating immunosuppression remain unknown, so future studies should use a proteomics approach to identify and modulate the effects of these factors to establish their role in brain tumor-associated systemic immune cell dysfunction.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 8) - April 2021
    April 1, 2021

    Table Of Contents

    Phospho-Tau217 Blood Biomarker May Help to Diagnose Early Alzheimer’s Disease

    Cognitive Deficits in Patients Recovering from COVID-19

    Polyradiculoneuropathy from Immune Checkpoint Inhibitors

    Brain Cancer and Brain Injury Drive Systemic Immunosuppression

    Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion

    Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes

    Atorvastatin and Low-Dose Dexamethasone for Treatment of Chronic Subdural Hematoma

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Dr. Isaacson (author) reports he is a consultant for Genentech/Roche and Biogen, Dr. Rubin (author) reports he is a consultant for Merck Sharpe & Dohme Corp., and Dr. Noch (author) reports he is a stockholder in Destroke, Inc. All of the relevant financial relationships listed for these individuals have been mitigated. None of the remaining authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing